Braveheart Bio, Inc. (BRVE) EBITDA
Braveheart Bio, Inc. (BRVE) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$15.88M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$381.00K; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | (m) | -$15.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-06-30 | Reported | (m) | -$381.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|